TY  - JOUR
AU  - Afshar-Oromieh, Ali
AU  - Haberkorn, Uwe
AU  - Zechmann, Christian
AU  - Armor, Thomas
AU  - Mier, Walter
AU  - Spohn, Fabian
AU  - Debus, Nils
AU  - Holland-Letz, Tim
AU  - Babich, John
AU  - Kratochwil, Clemens
TI  - Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095.
JO  - European journal of nuclear medicine and molecular imaging
VL  - 44
IS  - 6
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2017-01093
SP  - 950 - 959
PY  - 2017
AB  - Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies.Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with (131)I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy. The applied doses were separated in three groups: <3.5, 3.5-5.0 and >5.0 GBq. Antitumor and side-effects were analyzed by blood samples and other clinical data. Follow-up was conducted for up to 5 years.The best therapeutic effect was achieved by the first therapy. A PSA decline of ≥50
LB  - PUB:(DE-HGF)16
C6  - pmid:28280855
C2  - pmc:PMC5397661
DO  - DOI:10.1007/s00259-017-3665-9
UR  - https://inrepo02.dkfz.de/record/120667
ER  -